4D Molecular Therapeutics Stock (NASDAQ:FDMT)

Forecast Revenue Ownership Financials Chart

Previous Close

$15.91

52W Range

$9.44 - $36.25

50D Avg

$17.24

200D Avg

$22.18

Market Cap

$844.51M

Avg Vol (3M)

$867.43K

Beta

2.79

Div Yield

FDMT Company Profile

4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

201

IPO Date

Dec 11, 2020

Website

FDMT Performance

Revenue Breakdown

Revenue Breakdown by Product/Service

Product/Service	Dec 23	Dec 22	Dec 21
Collaboration And License Revenue	$20.01M	$3.13M	$18.04M

Fiscal year ends in Dec 23 | Currency in USD

FDMT Financial Summary

	Dec 23	Dec 22	Dec 21
Revenue	-	$3.13M	$18.04M
Operating Income	$-112.87M	$-110.03M	$-71.33M
Net Income	$-100.84M	$-101.08M	$-68.30M
EBITDA	$-112.87M	$-110.03M	$-71.33M
Basic EPS	-	$-3.12	$-2.46
Diluted EPS	-	$-3.12	$-2.46

Fiscal year ends in Dec 23 | Currency in USD

Peer Comparison

Ticker	Company
AKRO	Akero Therapeutics, Inc.
GOSS	Gossamer Bio, Inc.
CGEM	Cullinan Oncology, Inc.
RVMD	Revolution Medicines, Inc. Warrant
MLYS	Mineralys Therapeutics, Inc.
BMEA	Biomea Fusion, Inc.
EWTX	Edgewise Therapeutics, Inc.
STOK	Stoke Therapeutics, Inc.
IPSC	Century Therapeutics, Inc.
BDTX	Black Diamond Therapeutics, Inc.
REPL	Replimune Group, Inc.
BCEL	Atreca, Inc.
KRON	Kronos Bio, Inc.
PASG	Passage Bio, Inc.
CCCC	C4 Therapeutics, Inc.
FIXX	Q32 Bio Inc.
LYRA	Lyra Therapeutics, Inc.
NVCT	Nuvectis Pharma, Inc.